Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 Mar 1;109(3):511-518.
doi: 10.1097/TP.0000000000005135. Epub 2024 Jul 25.

Kidney Transplantation in Patients With aHUS: A Comparison of Eculizumab Prophylaxis Versus Rescue Therapy

Caroline Duineveld  1 , Emily K Glover  2 , Romy N Bouwmeester  3 , Nicole C A J van de Kar  3 , David Kavanagh  2 , Jack F M Wetzels  1 , Neil S Sheerin  2
Affiliations
Comparative Study

Kidney Transplantation in Patients With aHUS: A Comparison of Eculizumab Prophylaxis Versus Rescue Therapy

Caroline Duineveld et al. Transplantation. .

Abstract

Background: Guidelines advise eculizumab prophylaxis for most kidney transplant recipients with atypical hemolytic uremic syndrome (aHUS). However, recurrence rates may be overestimated, and starting eculizumab at relapse ("rescue therapy") may prevent graft loss. Randomized controlled trials have not compared the efficacy, safety, and costs of different treatment strategies. We performed a comparative study, including a previously described Dutch cohort treated with rescue therapy and a UK cohort using eculizumab prophylaxis.

Methods: In the Netherlands, we selected all adult patients with aHUS who received a kidney transplant between 2010 and 2021 in the Radboud University Medical Center (n = 30) and enriched this cohort with 8 patients who received rescue therapy in other centers. The UK cohort included all adult patients with aHUS at moderate or high risk of recurrence, transplanted between 2013 and 2017 with prophylactic eculizumab.

Results: We included 38 Dutch patients and 35 UK patients. Characteristics were comparable, although the UK cohort included more patients with a complement factor H SCR20 mutation or hybrid gene (31% versus 5%; P < 0.01), and more Dutch patients received living donor kidneys (66% versus 20%; P < 0.001). Follow-up was comparable (the Dutch patients 70.8 mo, range, 10-134; UK patients 55.4 mo, range, 2-95). Eighteen (47%) Dutch patients received rescue therapy. Death-censored graft survival was not significantly different (the Dutch patients 1 y, 3 y, and 6 y: 97.4%, 91.2%, and 87.1%, respectively; UK patients 1 y, 3 y, and 6 y: 97.1%, 88.2%, and 65.6%, respectively, log-rank P = 0.189).

Conclusions: In a population characterized by low prevalence of "very high risk" genes, who were predominantly transplanted using an endothelial protective regime, death-censored graft survival with eculizumab rescue therapy was not inferior to prophylaxis.

PubMed Disclaimer

Conflict of interest statement

N.C.A.J.v.d.K. and J.F.M.W. received grant support from the Dutch Board of Health Insurance Companies to conduct the CUREiHUS study. N.C.A.J.v.d.K. received consultancy fees from Roche Pharmaceuticals and Novartis and is a subinvestigator in the APL2-C3G trial, Apellis. J.F.M.W. received consultancy fees from Alexion and Novartis. C.D. is a subinvestigator in the APL2-G3G trial, Apellis. N.S.S. has provided consultancy for Alexion Pharmaceuticals. D.K. has received consultancy income from Gyroscope Therapeutics, Alexion Pharmaceuticals, Novartis, Apellis, and Sarepta. The other authors declare no conflicts of interest.

Figures

FIGURE 1.
FIGURE 1.
Death-censored graft survival. Kaplan-Meier analysis of death-censored renal graft survival in the Dutch cohort (the Netherlands; green), consisting of patients treated with a strategy of rescue therapy, and the UK cohort (blue), consisting of patients treated with a strategy of eculizumab prophylaxis. Numbers at risk in each group per 12-mo interval are indicated below the graph. Log-rank P = 0.189.
See this image and copyright information in PMC

References

    1. Fakhouri F, Loirat C. Anticomplement treatment in atypical and typical hemolytic uremic syndrome. Semin Hematol. 2018;55:150–158. - PubMed
    1. Le Quintrec M, Zuber J, Moulin B, et al. . Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant. 2013;13:663–675. - PubMed
    1. Goodship TH, Cook HT, Fakhouri F, et al. ; Conference Participants. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2017;91:539–551. - PubMed
    1. Zuber J, Le Quintrec M, Krid S, et al. ; French Study Group for Atypical HUS. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant. 2012;12:3337–3354. - PubMed
    1. Zuber J, Frimat M, Caillard S, et al. . Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2019;30:2449–2463. - PMC - PubMed

Publication types

MeSH terms

Substances